Canada markets close in 3 hours 40 minutes
  • S&P/TSX

    20,568.11
    -193.92 (-0.93%)
     
  • S&P 500

    4,522.59
    -54.51 (-1.19%)
     
  • DOW

    34,479.62
    -160.17 (-0.46%)
     
  • CAD/USD

    0.7790
    -0.0019 (-0.24%)
     
  • CRUDE OIL

    66.95
    +0.45 (+0.68%)
     
  • BTC-CAD

    70,636.37
    -2,376.47 (-3.25%)
     
  • CMC Crypto 200

    1,398.98
    -42.79 (-2.97%)
     
  • GOLD FUTURES

    1,781.50
    +18.80 (+1.07%)
     
  • RUSSELL 2000

    2,151.13
    -55.20 (-2.50%)
     
  • 10-Yr Bond

    1.3780
    -0.0700 (-4.83%)
     
  • NASDAQ

    15,014.61
    -366.71 (-2.38%)
     
  • VOLATILITY

    31.61
    +3.66 (+13.09%)
     
  • FTSE

    7,122.32
    -6.89 (-0.10%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • CAD/EUR

    0.6887
    -0.0018 (-0.26%)
     

Why Supernus' Acquisition of Adamas Is a Smart Move

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting